ALZN Company Profile and Key Details

ALZN has shown sold momentum, gaining 3.86% over the past week and 9.01% over the past quarter, though year-to-date performance is up 32.97%. Short-term trend indicators are bullishly aligned (SMA20 6.39%, SMA50 -0.25%, SMA200 -18.35%). The stock’s 14-day RSI is 53.33 (neutral), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.55% below its high and over 31.65% above its low. Average 10-day trading volume of 377.34 thousand shares is significantly above the 3-month average of 104.01 thousand, indicating heightened recent market interest.

Alzamend Neuro Inc has 3.80 million shares outstanding. The public float is 3.79 million shares, elevated short interest at 3.94% of float. This equals 149.01 thousand shares. The short ratio is 2.35 days. Institutional investors hold 3.97% of the float. Insiders own 2.26%. AULT MILTON C III holds 116.65 thousand shares, GUSTAFSON MARK has 60.00 thousand shares and Jackman Stephan has 45.50 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Alzamend Neuro Inc generated EPS of -$5.50 over the past year. Five-year average earnings growth is 30.49%. The latest quarter delivered EPS of -$0.58. The next quarter is forecast at -$0.53. Next year's EPS is expected at -$17.63. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $42.00. The high target offers 3650.0% upside. The low target suggests 3400.0% downside. The mean target is $43.00. This offers 3483.33% upside. Alzamend Neuro Inc earnings surprise history is frequent misses against expectations. The quarter that ended March 11, 2026, missed forecasts by 9.43%. The prior quarter beat by -63.86%. Over the last six quarters, Apple has recorded several small beats. These include -47.36% in September 12, 2024.

Alzamend Neuro Inc (NASDAQ:ALZN) closed at $1.08 USD, losing -$0.12 (-10.00%) from the previous close of $1.20. The stock is currently mid-range between its 52-week high and low $0.84 and $3.60. With a market capitalization of about $3.39 million, Alzamend Neuro Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~0.17). Key stats such as the average daily volume over the past year has been around 102.55 thousand shares, trading with heavier-than-usual volume. Headquartered in Atlanta, GA, Alzamend Neuro Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stephan Jackman, the company employs approximately 5 people and listed since June 15, 2021. Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

Our AI price prediction model suggests that Alzamend Neuro Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.83%, with price expected at $1.27 by July 14, 2026, within a range of $1.21 to $1.32 3-Month Outlook: Projected rise of 41.67%, reaching $1.70 by September 28, 2026, with a range of $1.39 to $1.86. 1-Year Outlook: Projected loss of -96.67%, with price at $0.04 by June 30, 2027, within a range of $0.00 to $4.02.

Alzamend Neuro Inc (NASDAQ:ALZN) shares are up 32.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Alzamend Neuro Inc trading at a premium to the broader market with a P/E of -0.26. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $27.21, suggesting 2167.5% upside. Our AI forecast model points to short-term strength (5.83% over two weeks), a medium-term rise (41.67% over three months), and a longer-term loss (-96.67% over one year), with expected trading ranges indicating moderate volatility.

Alzamend Neuro Inc trades at a P/E ratio of -0.26, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.09 suggesting the stock is closer to book value. The P/FCF stands at -0.61, also below market averages.

Alzamend Neuro Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.02. This means the shares are trading above this model’s fair value.